Tempus AI (TEM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, to be held virtually, with voting on director elections, auditor ratification, and say-on-pay frequency.
Only holders of Class A or Class B common stock as of March 27, 2026, are eligible to vote.
Proxy materials are available online, and multiple voting methods are provided, including internet, phone, mail, and during the meeting.
Voting matters and shareholder proposals
Shareholders will vote to elect nine directors, ratify PricewaterhouseCoopers LLP as auditor for 2026, and provide a non-binding advisory vote on the frequency of future say-on-pay votes.
Board recommends voting for all director nominees, for auditor ratification, and for a three-year frequency for say-on-pay.
Shareholder proposals for the 2027 meeting must be submitted by December 8, 2026, for proxy inclusion.
Board of directors and corporate governance
Board consists of nine members with diverse backgrounds in technology, healthcare, academia, and investment.
Majority of directors are independent per Nasdaq standards; committee memberships are structured for independence.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Executive Committees, each with defined charters.
Board leadership structure allows flexibility; currently, the CEO also serves as Chair.
Board emphasizes diversity, independence, and regular evaluation of governance practices.
Latest events from Tempus AI
- Diagnostics and data segments show strong growth, fueled by AI and strategic partnerships.TEM
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Virtual meeting to elect nine directors, ratify auditor, and set say-on-pay vote frequency.TEM
Proxy filing7 Apr 2026 - AI-driven insights from proprietary clinical and molecular data are reshaping precision medicine.TEM
Morgan Stanley Technology, Media & Telecom Conference 20263 Mar 2026 - Q4 and 2025 revenue rose 83% year-over-year, with strong Diagnostics and Data growth.TEM
Q4 202524 Feb 2026 - Q2 revenue up 25% to $166M, net loss $552M on IPO costs, cash at $479.7M.TEM
Q2 20242 Feb 2026 - Q3 revenue up 33% YoY; Ambry Genetics acquisition expands growth and capabilities.TEM
Q3 202416 Jan 2026 - AI-powered diagnostics and data platform drives 25% projected revenue growth for 2026.TEM
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Q4 revenue up 35.8%, 2025 guidance raised, and Ambry Genetics acquisition completed.TEM
Q4 20247 Jan 2026 - AI-powered diagnostics and data licensing drive growth, with applications set to lead future revenue.TEM
Morgan Stanley Technology, Media & Telecom Conference7 Jan 2026